Gene Expression Meta-Analysis Identifies VDAC1 as a Predictor of Poor Outcome in Early Stage Non-Small Cell Lung Cancer

BACKGROUND The bioenergetic status of non-small cell lung cancer correlates with tumour aggressiveness. The voltage dependent anion channel type 1 (VDAC1) is a component of the mitochondrial permeability transition pore, regulates mitochondrial ATP/ADP exchange suggesting that its over-expression could be associated with energy dependent processes including increased proliferation and invasiveness. To test this hypothesis, we conducted an in vivo gene-expression meta-analysis of surgically resected non-small cell lung cancer (NSCLC) using 602 individual expression profiles, to examine the impact of VDAC1 on survival. METHODOLOGY/PRINCIPAL FINDINGS High VDAC1 expression was associated with shorter overall survival with hazard ratio (HR) = 0.6639 (95% confidence interval (CI) 0.4528 to 0.9721), p = 0.035352 corresponding to 52 versus 101 months. VDAC1 predicted shorter time to recurrence and was shown to be an independent prognostic factor compared with histology, gender, age, nodal stage and tumour stage in a Cox multivariate analysis. Supervised analysis of all the datasets identified a 6-gene signature comprising HNRNPC, HSPA4, HSPA9, UBE2D2, CSNK1A1 and G3BP1 with overlapping functions involving regulation of protein turnover, RAS-RAF-MEK pathway and transcription. VDAC1 predicted survival in breast cancer and myeloma and an unsupervised analysis revealed enrichment of the VDAC1 signature in specific subsets. CONCLUSIONS In summary, gene expression analysis identifies VDAC1 gene expression as a predictor of poor outcome in NSCLC and other cancers and is associated with dysregulation of a conserved set of biological pathways, which may be causally associated with aggressive tumour behaviour.

[1]  Kazunari Taira,et al.  Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation. , 2003, Biochemical and biophysical research communications.

[2]  Jun Chen,et al.  Joint analysis of two microarray gene-expression data sets to select lung adenocarcinoma marker genes , 2004, BMC Bioinformatics.

[3]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[4]  N. Socci,et al.  Casein Kinase II Alpha Subunit and C1-Inhibitor Are Independent Predictors of Outcome in Patients with Squamous Cell Carcinoma of the Lung , 2004, Clinical Cancer Research.

[5]  S. Kaul,et al.  Activation of Wild Type p53 Function by Its Mortalin-binding, Cytoplasmically Localizing Carboxyl Terminus Peptides* , 2005, Journal of Biological Chemistry.

[6]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[7]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Hoek,et al.  Mitochondrial Binding of Hexokinase II Inhibits Bax-induced Cytochrome c Release and Apoptosis* , 2002, The Journal of Biological Chemistry.

[9]  N. Danial,et al.  Bad targets the permeability transition pore independent of Bax or Bak to switch between Ca2+-dependent cell survival and death. , 2009, Molecular cell.

[10]  R. Coleman,et al.  Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[12]  S. Chandna,et al.  Putative partners in Bax mediated cytochrome-c release: ANT, CypD, VDAC or none of them? , 2009, Mitochondrion.

[13]  Hanno Steen,et al.  Development of human protein reference database as an initial platform for approaching systems biology in humans. , 2003, Genome research.

[14]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[15]  D. Lauffenburger,et al.  Correction for Abu-Hamad et al., The expression level of the voltage-dependent anion channel controls life and death of the cell , 2006, Proceedings of the National Academy of Sciences.

[16]  YongSung Kim,et al.  Drosophila Porin/VDAC Affects Mitochondrial Morphology , 2010, PloS one.

[17]  M. V. Vander Heiden,et al.  Bcl-x l Promotes the Open Configuration of the Voltage-dependent Anion Channel and Metabolite Passage through the Outer Mitochondrial Membrane* , 2001, The Journal of Biological Chemistry.

[18]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[19]  M. Madesh,et al.  VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release , 2001, The Journal of cell biology.

[20]  J. Hoek,et al.  Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. , 2005, Cancer research.

[21]  E. Vallières.  Role of adjuvant systemic therapy for stage I NSCLC. , 2007, Thoracic surgery clinics.

[22]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[23]  C. Thompson,et al.  Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. , 2004, Molecular cell.

[24]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Igor Jurisica,et al.  Prognostic gene signatures for non-small-cell lung cancer , 2009, Proceedings of the National Academy of Sciences.

[26]  Mihee M. Kim,et al.  Modulation of p53 and MDM2 activity by novel interaction with Ras-GAP binding proteins (G3BP) , 2007, Oncogene.

[27]  Douglas G Altman,et al.  Key Issues in Conducting a Meta-Analysis of Gene Expression Microarray Datasets , 2008, PLoS medicine.

[28]  V. Shoshan-Barmatz,et al.  Downregulation of voltage-dependent anion channel-1 expression by RNA interference prevents cancer cell growth in vivo , 2010, Cancer biology & therapy.

[29]  L. Galluzzi,et al.  Disruption of the hexokinase–VDAC complex for tumor therapy , 2008, Oncogene.

[30]  Mark Gerstein,et al.  The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..

[31]  R. Franklin,et al.  Altered metabolism and mitochondrial genome in prostate cancer , 2006, Journal of Clinical Pathology.

[32]  Fabien Reyal,et al.  Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability , 2008, BMC Genomics.

[33]  C. Dooms,et al.  Association Between 18F-Fluoro-2-Deoxy-d-Glucose Uptake Values and Tumor Vitality: Prognostic Value of Positron Emission Tomography in Early-Stage Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Fidel Ramírez,et al.  Computing topological parameters of biological networks , 2008, Bioinform..

[35]  Cheng Wu,et al.  Expression of G3BP and RhoC in esophageal squamous carcinoma and their effect on prognosis. , 2007, World journal of gastroenterology.

[36]  G. Murray,et al.  Mortalin is over‐expressed by colorectal adenocarcinomas and correlates with poor survival , 2005, The Journal of pathology.

[37]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Sebastian Hiller,et al.  References and Notes Supporting Online Material Materials and Methods Figures S1 to S5 Table S1 References Solution Structure of the Integral Human Membrane Protein Vdac-1 in Detergent Micelles , 2022 .

[39]  M. V. Heiden,et al.  Bcl-xL prevents cell death following growth factor withdrawal by facilitating mitochondrial ATP/ADP exchange. , 1999, Molecular cell.

[40]  W. Craigen,et al.  Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death , 2007, Nature Cell Biology.

[41]  H. Zinszner,et al.  A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. , 1994, Genes & development.

[42]  Masashi Narita,et al.  Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC , 1999, Nature.

[43]  S. Korsmeyer,et al.  VDAC2 Inhibits BAK Activation and Mitochondrial Apoptosis , 2003, Science.

[44]  A I Saeed,et al.  TM4: a free, open-source system for microarray data management and analysis. , 2003, BioTechniques.

[45]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[46]  V. Shoshan-Barmatz,et al.  Voltage-dependent Anion Channel 1-based Peptides Interact with Hexokinase to Prevent Its Anti-apoptotic Activity* , 2009, Journal of Biological Chemistry.

[47]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[48]  H. Lee,et al.  Expression of type 2 hexokinase and mitochondria-related genes in gastric carcinoma tissues and cell lines. , 2007, Anticancer research.

[49]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[50]  N. Fu,et al.  A soluble form of the pilus protein FimA targets the VDAC-hexokinase complex at mitochondria to suppress host cell apoptosis. , 2010, Molecular cell.